A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.

Marco Vincenzo LentiVivien DolbyTanya ClarkVeronica HallSuzanne TattersallFrancesca FairhurstCatherine KennethRachael WalkerKaren KempSimon Borg-BartoloJimmy K LimdiJo TaylorTristan TownsendSree SubramanianDaniel StoreyArash AssadsangabiCatherine StansfieldPaul SmithDebra ByrneAnnalisa De SilvestriChristian Philipp Selinger

Published in: Alimentary pharmacology & therapeutics (2021)

Ustekinumab was effective and well tolerated in this real-world cohort. While ustekinumab proved more effective at 14-weeks, we found no statistically significant differences at 52 weeks compared to vedolizumab.

Keyphrases

ulcerative colitis
patients with inflammatory bowel disease
gestational age
preterm birth
clinical evaluation